Dennis Bastas CEO and MD Genepharm
Dennis is CEO and Managing Director of Genepharm, and was the founding force behind it’s initial creation and strategic development. Dennis has extensive experience is retail and supply chain strategies, having developed solutions for companies including Sigma, Australia Post, Linfox, 3M and National Australia Bank.

John Bronger Director Chemistworks Management

John Bronger is well known in Australian business and pharmacy, having served for 11 years as the National President of to the Pharmacy Guild of Australia. In addition, John has been a proprietor of community pharmacies for over 30 years. He was Director of the National Return and Disposal of Unwanted Medicines campaign, a member of the Australian Pharmaceutical Advisory Committee ?and an Adjunct Associate Professor in the Faculty of Pharmacy at University of Sydney.

Duncan Bucknell IP Strategist
Duncan uses intellectual property to drive success for his clients, strategically and globally. Duncan acts for generic clients on freedom to operate, early launch, and litigation strategy and for innovator clients on lifecycle management and IP litigation strategy.

Andrew Carter Managing Director Commercial Eyes

Andrew has worked in pharmaceutical training, sales management, marketing, business development and general management since 1990. Prior to entering the consulting profession, Andrew was responsible for Marketing and Business Development at Faulding Pharmaceuticals. In 2001, he established Commercial Eyes, which has become a leading healthcare commercialisation firm, providing consulting services to over 200 local and international clients.

Wayne Condon Principal Griffith Hack

Wayne practices in the area of intellectual property with an emphasis on patent litigation. He has in excess of 28 years’ experience advising in relation to and conducting intellectual property litigation in Australia and other jurisdictions. Wayne’s specific area of expertise is in the conduct of patent infringement and revocation proceedings and he has been involved in a number of Australia’s leading patent cases. Wayne’s involvement in those cases has often been as part of a global team in multi-jurisdictional proceedings. He is therefore particularly experienced in dealing with the unique issues which arise in global litigation of this kind. Wayne has particular experience and expertise in the pharmaceutical and biotechnology sector. He led the team in the Australian patent proceedings which clarified the law relating to the patentability of methods of medical treatment and he was a member of the team in the case which established an important set of guiding principles in Australia for determining when an interlocutory injunction order can be granted in pharmaceutical patent infringement cases.

Karl Cornelius Director Portfolio Management Hospira
Karl has over 10 years experience in the pharmaceutical industry, having held various roles for Faulding, Mayne Pharma and Hospira.  He has spent the last 6 years working specifically in portfolio management for Mayne Pharma and Hospira, where he has been in charge of the injectable generic, biogeneric and proprietary pipelines.

Kathryn Everett Partner Freehills
Kathryn Everett is a partner specialising in intellectual property, litigation.  Kathryn has extensive experience in the pharmaceutical, biotechnology and life sciences industries with clients including multi-national pharmaceutical companies, Australian based entities and Australian subsidiaries of international companies. Kathryn is head of the Freehills Pharmaceutical Focus Group.

Sam Everingham Director Stethoscope
Sam Everingham is Director of Stethoscope Research and has been providing market research to the healthcare sector for over 15 years. He has a Masters in Public Health as well as degrees in Psychology and Statistics. Sam has conducted groundbreaking studies into the use of complementary and generic medicines as well as evaluating the efficacy of patient loyalty programs.

Assoc Prof Tom Faunce College of Law, Faculty of Medicine ANU

Dr Thomas Faunce is an associate professor in both the College of Law and Medical School at the Australian National University. He is director of two large Australian Research Council grants investigating the impact of international trade agreements on Australian medicines policy and safety and cost-effectiveness regulation of nanomedicine in Australia. He was a keynote speaker at the European Generic Medicines Conference in Berlin in 2007.

Elizabeth Frost President Australian Pharmacy Council

Elizabeth Frost, a registered pharmacist since 1964, was a partner in two pharmacies in Wamberal for over 30 years. She is a Fellow of both the Pharmaceutical Society, and the Australian College of Pharmacy Practice. Elected to the Pharmacy Board of NSW in 1996, she was the appointed President from 1998 until standing down in 2007. She was the first woman President in the 100 year history of the Board. Currently Elizabeth is President of the Australian Pharmacy Council, the body representing the Pharmacy Boards of Australia and also Deputy Chairman of the Australian Pharmacy Examining Committee.

Andrew Goodsall Senior Healthcare Analyst UBS

Andrew is the senior healthcare analyst with UBS Australia. He and his team have been rated the number one healthcare equities research team in each of the major surveys since 2003. Until 1999 he was senior adviser/chief of staff to the health minister in the Kennett Government, with responsibilities for advice on 120 public hospitals, episodic funding, medical research funding and privatisation programmes.

Odette Gourley Partner Corrs ChambersWestgarth

Odette has over 20 years experience in intellectual property law, having joined Corrs in 2007 from another major law firm. She is an expert on brand strategy, trade mark portfolio management and and advertising law, acting for major multinational brand owning-companies across all consumer product and service sectors; and well known for her involvement in important IP, regulatory, advertising and product liability issues affecting regulated products including prescription, OTC and complementary medicines.

Leighton Howard Managing Director GenericsWeb

Leighton Howard is the founder and Managing Director of XIP and GenericsWeb, a provider of Generic Pharmaceutical Intelligence to government institutions, legal practices and industry firms in over 30 countries.  He also acts as a consultant in the development of generic pharmaceuticals, specialising in patent strategy. Leighton has extensive experience in patent searching and information management, starting off as a professional patent searcher with RWS. He then moved into generic pharma IP, taking a position at IVAX Pharmaceuticals (UK) where he was responsible for meeting the patent information needs for the global generic development portfolio.

Michael Ison Business Unit Director DHL

As the Director of Operations Mike has the responsibility for the Australian DHL Exel Supply Chain Healthcare business and has been the strategic driver in the success of this organisation since it began as TLC in Australia in 1998. Mike has more than 30 years experience in Australian Logistics operations with a broad background in various aspects of Warehousing and Distribution operations. For the past 10 years Mike has been a leader in the development of Healthcare Supply Chain solution in Australia, successfully creating various opportunities to deliver real value for the industry and respective stakeholders.

Michael Johnston Senior Health Policy Officer CHOICE
Michael Johnston is Senior Health Policy Officer at CHOICE (formerly the Australian Consumers Association). Before joining CHOICE in 2007, Michael worked for 7 years in the Commonwealth public service, most recently at Treasury, on both health policy and competition and consumer policy.

Saul Mashaal Chairman & CEO SciGen Group

Saul has over 40 years experience in the Biopharmaceutical industry.  He started his career with Syntex (now Roche Bioscience), followed by a distinguished tenure with 3M, where he was head of International Business Development of the Health & Sciences Sector. Since founding SciGen in 1988, Saul has overseen the company deliver biotech-derived human healthcare products across Asia Pacific, Europe and the Americas.

Kim O'Connell Partner Mallesons Stephen Jaques

Kim O'Connell is a Partner in the Sydney office of Mallesons Stephen Jaques where she specialises in intellectual property law. Her focus on intellectual property includes protection, enforcement and exploitation of intellectual property rights. Kim has extensive experience of patent disputes and has represented clients in a number of matters involving biotechnological, pharmaceutical inventions and medical devices

Tim Oldham President Asia Pacific Hospira
Tim’s been Hospira’s President Asia Pacific since Hospira acquired Mayne Pharma in February 2007. Prior to that he held a variety of business development, strategic marketing and integration roles for Mayne in Europe. In addition, he was involved in Mayne’s entry into biogenerics and was Chair of the Biosimilars and Biotechnology Committee of the European Generic Medicines Association.

KR Rao Managing Director Orchid Pharmaceuticals
Shri K Raghavendra Rao is the Founder and Managing Director of Orchid. Prior to establishing Orchid, he was associated with leading organisations in India in various capacities. He was singularly responsible for developing a multi-business conglomerate in the Gulf, which included the region’s first ever bulk drugs plant. He is also a member of The Institute of Company Secretaries of India.

Alek Safarian CEO Novotech
Alek Safarian is founder and CEO of Novotech, Australia’s leading CRO. He holds an MBA and Bachelor of Pharmacy from the University of Sydney, and is a member of The Association of Regulatory and Clinical Scientists (ARCS) and the Drug Information Association. He is also a Registered Pharmacist with the NSW Pharmacy Board.

Prof Emeritus Lloyd Sansom Chair PBAC
Professor Sansom was appointed the Chair of the Pharmaceutical Benefits Advisory Committee in January 2001, having been the Chair of the Australian Pharmaceutical Advisory Council since 1991. He was involved in the development of Australia’s National Medicines Policy, and in recognition of these contributions he was made an Officer in the Order of Australia in 2002.

Michael Schildkraut General Manager Sandoz

Michael was appointed General Manager of Sandoz Australia in February after having joined the company as Commercial Operations Manager in September 2007. Before joining Sandoz, Michael worked within the Novartis Group's Consumer Health Division in Sydney, where he held numerous roles in the Novartis Animal Health Business Unit including Strategic Development Manager - Asia Pacific, and Managing Director - ANZ. Prior to joining Novartis in 2000, Michael worked for Schering-Plough and Mallinckrodt in various Marketing roles. Michael holds a B.Sc., BVMS, & an MBA, and serves on the Board of the Generic Medicines Industry Association.

Perry Stam Director of Strategic Partners IMS Health

In his current role with IMS, Perry manages the Data Acquisition and Industry Alliances function which includes contractual oversight in respect of Confidentiality, Privacy, and IP protection. Perry has had extensive background in the Pharmaceutical Industry both in Australia and the Asia Pacific Region including Japan with Wyeth, Sanofi, and Wellcome (now GSK). During his career Perry has held senior positions in Supply Chain Management and Commercial Operations support, with exposure to global ERP deployment projects such as JD Edwards and SAP, as well as major multi-market inventory and forecasting optimization initiatives. Perry holds a Master of Business degree in Operations Management from the University of Technology, Sydney, and has attended a number of management and marketing studies at the Wharton School - University of Pennsylvania, and the London Business School.

event sponsors Associate Sponsor:     Cocktail Sponsor:       Lunch Sponsor:       Exhibitor:   Media Partners:   sponsorship opportunities Generic Medicines Australia 2008 is an unrivalled and cost-effective sales and marketing solution:  Benefit from reaching the decision makers from your target industries Showcase your products and solutions Recieve branding on conference promotion from now until the event   Target your market!   For details contact Jack Mortlock